Amylyx Pharmaceuticals (AMLX) FCF Margin (2021 - 2024)
Amylyx Pharmaceuticals (AMLX) posted quarterly FCF Margin of 9281.13% for Q4 2024, up 926897.0% year-over-year from N/an in Q1 2024, and up 192.92% quarter-over-quarter from 9988.22% in Q3 2024.
Amylyx Pharmaceuticals (AMLX) FCF Margin (2021 - 2024) Analysis & Trends
Amylyx Pharmaceuticals' FCF Margin history runs 4 years deep, the most recent figure standing at 9281.13% for Q4 2024.
- In Q4 2024, FCF Margin rose 926897.0% year-over-year to 9281.13%; the TTM figure through Sep 2025 stood at 24295.6% (up 2434374.0% YoY), while the FY2024 annual figure was 192.0%, down 19480.0% from the prior year.
- FCF Margin for Q4 2024 stood at 9281.13%, up from 9988.22% in the prior quarter.
- The five-year high for FCF Margin was 9281.13% in Q4 2024, with the low at 12619.42% in Q3 2022.
- The 4-year median for FCF Margin is 7.45% (2023), against an average of 2494.63%.
- The sharpest annual moves came in 2023 and 2024: FCF Margin soared 1261404 bps in 2023, then plunged 998284 bps in 2024.
- Amylyx Pharmaceuticals' FCF Margin stood at 7374.74% in 2021, then soared by 97 bps to 229.92% in 2022, then soared by 105 bps to 12.17% in 2023, then surged by 76181 bps to 9281.13% in 2024.
- Business Quant data shows AMLX's FCF Margin at 9281.13% in Q4 2024, 9988.22% in Q3 2024, and 6517.01% in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.65 Bn | 42.68 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.09 Bn | 39.44 Bn | 2.15 Bn | 7.41% |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 21.80% |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 14.87% |
| 5 | United Therapeutics | 22.11 Bn | 19.45 Bn | 683.80 Mn | 26.25% |
| 6 | Viatris | 18.77 Bn | 17.88 Bn | 1.46 Bn | 8.76% |
| 7 | Neurocrine Biosciences | 15.62 Bn | 15.23 Bn | 935.80 Mn | 13.41% |
| 8 | Elanco Animal Health | 12.07 Bn | 11.54 Bn | 798.00 Mn | 17.84% |
| 9 | Dr Reddys Laboratories | 10.09 Bn | 9.93 Bn | - | - |
| 10 | Amylyx Pharmaceuticals | 4.36 Bn | 4.36 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 9,281.13% |
| Sep 30, 2024 | -9,988.22% |
| Jun 30, 2024 | -6,517.01% |
| Mar 31, 2024 | -0.63% |
| Dec 31, 2023 | 12.17% |
| Sep 30, 2023 | -5.38% |
| Jun 30, 2023 | 8.48% |
| Mar 31, 2023 | -7.45% |
| Dec 31, 2022 | -229.92% |
| Sep 30, 2022 | -12,619.42% |
| Sep 30, 2021 | -7,374.74% |